Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 22;12(2):265.
doi: 10.3390/cancers12020265.

Proteasome Inhibitors for the Treatment of Multiple Myeloma

Shigeki Ito  1
Affiliations
Review

Proteasome Inhibitors for the Treatment of Multiple Myeloma

Shigeki Ito. Cancers (Basel). .

Abstract

Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting. The first-in-class PI, bortezomib, was approved by the US food and drug administration in 2003. Carfilzomib is a next-generation PI, which selectively and irreversibly inhibits proteasome enzymatic activities in a dose-dependent manner. Ixazomib was the first oral PI to be developed and has a robust efficacy and favorable safety profile in patients with multiple myeloma. These PIs, together with other agents, including alkylators, immunomodulatory drugs, and monoclonal antibodies, have been incorporated into several regimens. This review summarizes the biological effects and the results of clinical trials investigating PI-based combination regimens and novel investigational inhibitors and discusses the future perspective in the treatment of multiple myeloma.

Keywords: bortezomib; carfilzomib; ixazomib; multiple myeloma; proteasome inhibitors.

PubMed Disclaimer

Conflict of interest statement

S.I. received honorarium from Celgene, Bristol-Myers Squibb, Takeda, Ono, and Janssen.

Figures

Figure 1
Figure 1
Molecular effects of proteasome inhibition on multiple myeloma cells.
See this image and copyright information in PMC

References

    1. Palumbo A., Anderson K. Multiple myeloma. N. Engl. J. Med. 2011;364:1046–1060. doi: 10.1056/NEJMra1011442. - DOI - PubMed
    1. Anderson K.C. The 39th David A. Karnofsky lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma. J. Clin. Oncol. 2012;30:445–452. doi: 10.1200/JCO.2011.37.8919. - DOI - PMC - PubMed
    1. Kumar S.K., Dispenzieri A., Lacy M.Q., Gertz M.A., Buadi F.K., Pandey S., Kapoor P., Dingli D., Hayman S.R., Leung N., et al. Continuous improvement in survival in multiple myeloma: Changes in elderly mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128. doi: 10.1038/leu.2013.313. - DOI - PMC - PubMed
    1. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., et al. A randomized comparison of bortezomib with high-dose dexamethasone in relapsed multiple myeloma. N. Engl. J. Med. 2005;352:2487–2498. doi: 10.1056/NEJMoa043445. - DOI - PubMed
    1. Herndon T.M., Deisseroth A., Kaminskas E., Kane R.C., Koti K.M., Rothmann M.D., Habtemariam B., Bullock J., Bray J.D., Hawes J., et al. US Food and Drug Administration approval: Carfilzomib for the treatment of multiple myeloma. Clin. Cancer. Res. 2013;19:4559–4563. doi: 10.1158/1078-0432.CCR-13-0755. - DOI - PubMed